Novocure mid-stage trial for electric fields device succeeds in pancreatic cancer
Source: SeekingAlpha
2026-03-26 07:43:18 ET
More on NovoCure
- NovoCure Limited 2025 Q4 - Results - Earnings Call Presentation
- NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
- NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching
- NovoCure outlines $675M–$705M 2026 revenue target as new indications fuel growth
- NovoCure Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Novocure mid-stage trial for electric fields device succeeds in pancreatic cancer
Zai Lab Limited
NASDAQ: ZLAB
ZLAB Trading
-0.81% G/L:
$20.72 Last:
156,787 Volume:
$20.69 Open:
ZLAB Latest News
April 01, 2026 07:30:00 am
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager TherapyMarch 17, 2026 04:35:00 pm
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)February 26, 2026 07:00:00 am
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate UpdatesZLAB Stock Data
$2,174,273,322
105,108,310
0.9%
39
N/A
Biotechnology & Life Sciences
Healthcare
CN
Shanghai
